Concomitant medications during immune checkpoint blockage in cancer patients: novel insights in this emerging clinical scenario
G Rossi, A Pezzuto, C Sini, A Tuzi, F Citarella… - Critical Reviews in …, 2019 - Elsevier
The use of immune checkpoint inhibitors (ICIs) in cancer patients is rapidly growing.
However, the potential impact of some widely used concomitant medications is still largely …
However, the potential impact of some widely used concomitant medications is still largely …
Immunotherapy in head and neck cancer: The great challenge of patient selection
M Napolitano, FM Schipilliti, L Trudu… - Critical reviews in oncology …, 2019 - Elsevier
The development of immune checkpoint inhibitors (ICIs) revolutionized the therapeutic
landscape in head and neck cancer. However, the majority of patients present primary …
landscape in head and neck cancer. However, the majority of patients present primary …
Perilesional edema in brain metastases: potential causes and implications for treatment with immune therapy
TT Tran, A Mahajan, VL Chiang, SB Goldberg… - … for immunotherapy of …, 2019 - Springer
Background Little is known about tumor-associated vasogenic edema in brain metastasis,
yet it causes significant morbidity and mortality. Our purpose was to characterize edema in …
yet it causes significant morbidity and mortality. Our purpose was to characterize edema in …
Concomitant use of corticosteroids and immune checkpoint inhibitors in patients with solid neoplasms: a real-world experience from a tertiary cancer center
Results: A total of 155 patients were identified to have received CPI during the study period,
of which 38 (24.5%) patients received steroids with prednisolone equivalent of≥ 10 mg/day …
of which 38 (24.5%) patients received steroids with prednisolone equivalent of≥ 10 mg/day …
Non-small-cell lung cancer: what are the benefits and challenges of treating it with immune checkpoint inhibitors?
Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape of advanced
non-small-cell lung cancer (NSCLC). It has improved the overall survival in the first-and …
non-small-cell lung cancer (NSCLC). It has improved the overall survival in the first-and …
Is there room for immune checkpoint inhibitors in patients who have NSCLC with autoimmune diseases?
Immune checkpoint inhibitors (ICIs) have changed the treatment paradigm and prognosis in
advanced NSCLC. 1 However, some subgroups of patients with NSCLC are usually not …
advanced NSCLC. 1 However, some subgroups of patients with NSCLC are usually not …
[HTML][HTML] Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis
Background For the management of immune checkpoint inhibitor (ICI)-induced pneumonitis
(ICI-pneumonitis), discontinuation of ICIs and high dose corticosteroid based on grade are …
(ICI-pneumonitis), discontinuation of ICIs and high dose corticosteroid based on grade are …
A Case of Long‐Term Survival after Checkpoint Inhibitor Pneumonitis in a Patient with Squamous Cell Lung Cancer
H Ashinuma, S Mizuno, Y Yoshida… - Case Reports in …, 2019 - Wiley Online Library
The management of grade 1 checkpoint inhibitor pneumonitis (CIP) is to withhold immune
checkpoint inhibitors; however, the natural history of this condition is unknown. We herein …
checkpoint inhibitors; however, the natural history of this condition is unknown. We herein …
Progress of Steroids Effect on Efficacy of Immune Checkpoint Inhibitors
G Pan, Y Fan - Zhongguo fei ai za zhi= Chinese Journal of Lung …, 2019 - europepmc.org
免疫检查点抑制剂 (immune checkpoint inhibitors, ICIs) 包括程序性死亡受体-1/配体-1
单抗和细胞毒性 T 淋巴细胞相关抗原-4 单抗等, 因其良好的抗肿瘤活性, 目前已被批准用于多种 …
单抗和细胞毒性 T 淋巴细胞相关抗原-4 单抗等, 因其良好的抗肿瘤活性, 目前已被批准用于多种 …
Progress of Steroids Effect on Efficacy of Immune Checkpoint Inhibitors.
PAN Guoqiang, FAN Yun - Chinese Journal of Lung Cancer, 2019 - search.ebscohost.com
Immune checkpoint inhibitors (ICIs), including programmed death receptor-1 (PD-l)/ligand
(PD-L1) and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) monoclonal antibody …
(PD-L1) and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) monoclonal antibody …